Evaluation on the Use of Afatinib Alone or Combined with Other Drugs in Clinical Trials

Journal of International Translational Medicine

Yong-qian SHU¹  Lian-ke LIU¹ 

[1]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China

关键词: Afatinib;    Clinical trials;    Non-small cell lung cancer;    Single-drug regimen;   

DOI  :  10.11910/2227-6394.2016.04.02.03

来源: DOAJ

【 摘 要 】

Afatinib, an oral tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER-2) and HER4, has been approved in treating patients with EGFR-mutation positive non-small cell lung cancer (NSCLC). Additionally, it also has efficacy in other tumors. Currently, the recommended dose of afatinib is 40 mg once daily, but in clinical trials, the other doses are also used. This article mainly summarized the usage of afatinib alone or combined with other drugs in clinical trials, hoping to provide a better treatment reference for its clinical application.

【 授权许可】

Unknown